HR Execs on the Move

SOBR Safe

www.sobrsafe.com

 
Creating detection devices that increase productivity and save lives. Based in Boulder, CO the company integrates innovative technologies in various device platforms through strategic partnerships, licensing agreements and acquisitions. Currently we are pilot testing with international employers our first patented and proprietary device SOBRCheck, a non-invasive, touch-based identity verification and alcohol detection solution.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sobrsafe.com
  • 885 Arapahoe Avenue
    Boulder, CO USA 80302
  • Phone: 844.762.7723

Executives

Name Title Contact Details

Similar Companies

MEDICAL EQUIPMENT RESOURCES

MEDICAL EQUIPMENT RESOURCES is a Woodlyn, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Blue Note Therapeutics

Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to helping patients live better.

Oncura

Oncura is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biodirection

NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.